123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes | Clinical Trial | StuddyBuddy@endsection 123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05698784

123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes

Conditions: Parkinson

Sex: All
Ages: 18 Years – N/A
Enrollment: 723
Sponsor: Assistance Publique - Hôpitaux de Paris

Location: France

Summary

123I-FP-CIT SPECT (DaTSCAN®) allows to detect presynaptic dopamine neuronal denervation. It is recommended to differentiate neurodegenerative parkinsonism from secondary parkinsonian syndromes or from essential tremor, and to distinguish patients with suspected dementia with Lewy bodies and those with other subtypes of dementia. The aim of this retrospective study was to evaluate the relevance of 123I-FP-CIT SPECT prescriptions, the profile of prescribers and the evolution of the prescription rate over a ten-year period.

Eligibility Criteria

Inclusion Criteria:Parkinsonian patients who benefited from a 123I-FP-CIT SPECTExclusion criteria:

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05698784). StuddyBuddy aggregates publicly available trial information.